GlaxoSmithKline: Pulmonary Disease, Chronic Obstructive trials

The registry lists 276 Pulmonary Disease, Chronic Obstructive studies with GlaxoSmithKline as lead sponsor. 7 are open to participants now and 141 have results posted.

Phase 1 84Phase 2 47Phase 3 65Phase 4 38No phase 43(a study in two phases counts in both)

Studies

Page 3 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Korean Chronic Obstructive Pulmonary Disease(COPD) Assessment Test Validation StudyCompletedNCT01424527
• Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating TreatmentCompletedNCT01395875
• Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post ExacerbationCompletedNCT01381458
• A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719CompletedNCT01362257Phase 1
• Characterisation of Healthy Volunteers, Asthma and Chronic Obstructive Pulmonary Disease Patients for Inhalation Profile, Pharyngometry, Spirometric Indices and Lung MorphometryCompletedNCT01345266Phase 1
• Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)CompletedNCT01332409
• A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01319019Phase 2
• A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.CompletedNCT01286831Phase 1
• Blood Levels and Effects of GSK1325756 in Healthy Adult Volunteers Aged 40 to 80 Years OldCompletedNCT01267006Phase 1
• A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment.CompletedNCT01266980Phase 1
• Predictive Ability of the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients With COPDCompletedNCT01254032
• Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump InhibitorsCompletedNCT01209104Phase 1
• First Time in Human Study With GSK1325756CompletedNCT01209052Phase 1
• Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy SubjectsCompletedNCT01128634Phase 1
• GSK573719 IV Enabling StudyCompletedNCT01110018Phase 1
• A Study of GSK573719 in Healthy Japanese Male SubjectsCompletedNCT01013974Phase 1
• Prevalence of Chronic Airway Obstruction in Subjects With a History of Cigarette Smoking in a Primary Care SettingCompletedNCT01013948
• Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese SubjectsCompletedNCT00976144Phase 1
• Phase I Study of GSK233705 in Healthy Japanese Male SubjectsCompletedNCT00964405Phase 1
• Phase I Study of GW642444M in Healthy Japanese Male SubjectsCompletedNCT00964249Phase 1
• Clinical Study to Assess the Effects of SRT2104 and Prednisolone on Biomarkers in Blood in Healthy VolunteersCompletedNCT00920660Phase 1
• Drug Interaction Study to Investigate Co-administration of GW642444M With KetoconazoleCompletedNCT00866515Phase 1
• A Healthy Volunteer Study With Inhaled GSK573719 and PlaceboCompletedNCT00803673Phase 1
• A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy SubjectsCompletedNCT00783003Phase 1
• A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By InjectionCompletedNCT00711126Phase 1
• A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic PatientsCompletedNCT00702910Phase 1
• Single Dose Escalation Study FTIM in Order to Assess Safety and Tolerability of GSK610677CompletedNCT00694902Phase 1
• A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.CompletedNCT00671216Phase 1
• Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00662805
• A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00642148Phase 2
• Repeat Dose Study in Male Healthy Volunteer SmokersCompletedNCT00615576Phase 1
• To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult MalesCompletedNCT00599612Phase 1
• To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]SB-681323 in Healthy Adult MalesCompletedNCT00564746Phase 1
• Effect of GSK1160724 In Healthy VolunteersCompletedNCT00555022Phase 1
• Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled OzoneCompletedNCT00551811Phase 1
• Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT00549679Phase 2
• Treatment Of Partial Reversible Chronic Obstructive Pulmonary DiseaseCompletedNCT00549146Phase 3
• Optimising the Propranolol Block ModelCompletedNCT00549120Phase 1
• Effect of GSK704838 In Healthy VolunteersCompletedNCT00539825Phase 1
• A Study to Examine the Effect of Particle Size on Bioequivalence and BioavailabilityCompletedNCT00517543Phase 1
• Endotoxin Challenge Study For Healthy Men and WomenCompletedNCT00515268Phase 1
• A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult SubjectsCompletedNCT00504439Phase 1
• Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705CompletedNCT00500461Phase 1
• A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD PatientsCompletedNCT00478738Phase 2
• A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy VolunteersCompletedNCT00475436Phase 1
• Safety, Blood Levels and Effects of GW642444CompletedNCT00469040Phase 1
• A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic PatientsCompletedNCT00463697Phase 1
• A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.CompletedNCT00453687Phase 1
• A Study To Look At The Safety Of SB-681323 In Healthy Adult Subjects After Intravenous Administration Of A Single DoseCompletedNCT00439881Phase 1
• Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00422604Phase 2
• Shortness Of Breath Questionnaire Validation StudyWithdrawnNCT00411372Phase 3
• Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).CompletedNCT00404261Phase 4
• A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)CompletedNCT00392587Phase 2
• Effects Of Oral Prednisolone On Bone Metabolism In Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00384306Phase 1
• Study to Assess GW642444 in Asthma PatientsCompletedNCT00381667Phase 2
• Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) PatientsCompletedNCT00380133Phase 1
• Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00379730Phase 1
• Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00376714Phase 2
• GSK159802 In Healthy Male Subjects And AsthmaticsCompletedNCT00364273Phase 1
• SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT00361959Phase 4
• Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic PatientsCompletedNCT00358488Phase 2
• Chronic Obstructive Pulmonary Disease Endpoints StudyCompletedNCT00358358Phase 4
• Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate AsthmaCompletedNCT00354666Phase 2
• Repeat Doses Of A New Medication (GW642444) In Asthmatic PatientsCompletedNCT00347139Phase 2
• ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.TerminatedNCT00346749Phase 4
• SERETIDE Plus Tiotropium Versus Individual ComponentsCompletedNCT00325169Phase 2
• Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate EndpointsCompletedNCT00292552
• Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00279019Phase 1
• Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)CompletedNCT00269126Phase 3
• Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00268216Phase 3
• Airway Inflammation In Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00268177Phase 3
• Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00259909
• ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.CompletedNCT00144911Phase 4
• Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00144859Phase 2
• Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease ExacerbationsCompletedNCT00115492Phase 4
• Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)CompletedNCT00103922Phase 3